Press centre

Latest

12 Feb 2021
GARDP Welcomes Additional Funding from UK to Develop New Treatment for Gonorrhoea
The UK government has announced an additional £1.5 million of funding to develop a new treatment for gonorrhoea. This investment, on top of £3.5 million committed in 2019, will support GARDP in the development and availability of zoliflodacin, a novel antibiotic, which is currently being assessed as part of a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
Read more